Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Malignant Pleural Mesothelioma
Interventions
DIAGNOSTIC_TEST

E-Nose testing

At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.

DIAGNOSTIC_TEST

Research blood

Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Consent Only), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Consent Only), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Consent Only), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only ), Montvale

All Listed Sponsors
collaborator

UNIVERSITY CAMPUS BIO-MEDICO, ITALY

UNKNOWN

lead

Memorial Sloan Kettering Cancer Center

OTHER